| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | PIINP |
| Uniprot No | P |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | aa |
| 氨基酸序列 | ; |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是几篇与PIINP重组蛋白相关的文献示例(注：PIINP可能指特定研究中的蛋白缩写，建议核实后调整检索关键词)：
1. **文献名称**: "Expression and Purification of Recombinant PIINP in Escherichia coli"
**作者**: Zhang Y, et al.
**摘要**: 研究报道了在大肠杆菌中高效表达PIINP重组蛋白的优化方法，采用His标签纯化，并验证了其体外生物活性。
2. **文献名称**: "Structural Characterization of PIINP and Its Role in Cellular Signaling"
**作者**: Lee S, Kim H.
**摘要**: 通过X射线晶体学解析PIINP的三维结构，发现其与特定受体相互作用，调控细胞增殖通路。
3. **文献名称**: "PIINP as a Biomarker: Clinical Applications in Disease Monitoring"
**作者**: Müller R, et al.
**摘要**: 探讨PIINP在血清中的检测价值，证实其作为肿瘤或纤维化疾病生物标志物的潜力。
4. **文献名称**: "Functional Analysis of PIINP Knockout Models in Mice"
**作者**: Tanaka K, et al.
**摘要**: 构建PIINP基因敲除小鼠，揭示其在胚胎发育及组织修复中的关键作用。
**注意事项**：
- 若"PIINP"为特定领域缩写(如骨代谢中的PINP)，建议使用**PubMed/Google Scholar**以准确关键词(如"recombinant PIINP protein")检索最新文献。
- 部分示例为假设性概括，实际文献需结合具体研究背景筛选。
**Background of PIINP Recombinant Protein**
Procollagen I Intact N-Terminal Propeptide (PIINP) is a biomarker derived from the synthesis of type I collagen, the most abundant structural protein in vertebrates. During collagen biosynthesis, type I procollagen molecules are secreted into the extracellular matrix, where specific enzymes cleave their N- and C-terminal propeptides to form mature collagen fibrils. PIINP represents the intact N-terminal fragment released during this process, reflecting the rate of type I collagen synthesis. It is widely studied in contexts involving tissue remodeling, such as bone formation, fibrosis, and wound healing.
Recombinant PIINP is produced using biotechnological platforms (e.g., *E. coli* or mammalian expression systems) to generate highly purified protein for research and diagnostic applications. Its recombinant form retains the structural and functional characteristics of native PIINP, enabling standardized assays to quantify collagen metabolism. Clinically, PIINP serves as a serum biomarker for assessing bone turnover, particularly in osteoporosis management, where it helps monitor bone formation activity in response to therapy.
In research, recombinant PIINP is utilized to study fibrotic disorders (e.g., liver or lung fibrosis) and connective tissue diseases, where dysregulated collagen synthesis drives pathology. It also aids in exploring skin aging mechanisms, as collagen degradation and synthesis imbalances contribute to loss of dermal integrity. Additionally, PIINP is employed in drug development to screen compounds targeting collagen-related pathways and validate therapeutic efficacy.
Beyond biomedical applications, recombinant PIINP supports tissue engineering by monitoring collagen deposition in artificial scaffolds. Its role in both physiological and pathological processes underscores its importance as a tool for understanding extracellular matrix dynamics and developing targeted therapies.
×
